Impact of preventive therapy on the risk of breast cancer among women with benign breast disease  by Cuzick, Jack et al.
lable at ScienceDirect
The Breast 24 (2015) S51eS55Contents lists avaiThe Breast
journal homepage: www.elsevier .com/brstOriginal articleImpact of preventive therapy on the risk of breast cancer among
women with benign breast disease
Jack Cuzick*, Ivana Sestak, Mangesh A. Thorat
Centre for Cancer Prevention, Wolfson Institute of Preventive Medicine, Barts & The London School of Medicine and Dentistry, Queen Mary University of
London, United KingdomKeywords:
Benign breast disease
Breast cancer prevention
Atypical hyperplasia
Breast cancer risk
Tamoxifen
Aromatase inhibitorsAbbreviations: AH, atypical hyperplasia; ADH,
BCRAT, breast cancer risk assessment tool; DCIS, d
hazard ratio; LCIS, lobular carcinoma in situ; OR, odds
lobular units.
* Corresponding author. Centre for Cancer Prevent
ventive Medicine, Barts & The London School of Me
Mary University of London, Charterhouse Square,
Kingdom. Tel.: þ44 (0)20 7882 3518.
E-mail address: j.cuzick@qmul.ac.uk (J. Cuzick).
http://dx.doi.org/10.1016/j.breast.2015.07.013
0960-9776/© 2015 The Authors. Published by Elseviea b s t r a c t
There are three main ways in which women can be identiﬁed as being at high risk of breast cancer i)
family history of breast and/or ovarian cancer, which includes genetic factors ii) mammographically
identiﬁed high breast density, and iii) certain types of benign breast disease. The last category is the least
common, but in some ways the easiest one for which treatment can be offered, because these women
have already entered into the treatment system. The highest risk is seen in women with lobular carci-
noma in situ (LCIS), but this is very rare. More common is atypical hyperplasia (AH), which carries a 4e5-
fold risk of breast cancer as compared to general population. Even more common is hyperplasia of the
usual type and carries a roughly two-fold increased risk. Women with aspirated cysts are also at
increased risk of subsequent breast cancer.
Tamoxifen has been shown to be particularly effective in preventing subsequent breast cancer in
women with AH, with a more than 70% reduction in the P1 trial and a 60% reduction in IBIS-I. The
aromatase inhibitors (AIs) also are highly effective for AH and LCIS. There are no published data on the
effectiveness of tamoxifen or the AIs for breast cancer prevention in womenwith hyperplasia of the usual
type, or for women with aspirated cysts.
Improving diagnostic consistency, breast cancer risk prediction and education of physicians and pa-
tients regarding therapeutic prevention in women with benign breast disease may strengthen breast
cancer prevention efforts.
© 2015 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).Benign breast disease and breast cancer risk
It has been known for some time that womenwith certain types
of benign breast disease are at an increased risk of developing
breast cancer. A seminal paper was published in 1985 by Dupont
and Page [1] who analysed a cohort of 3303 women with histo-
logically conﬁrmed benign breast disease who had been followed
up for a median of 17 years. They showed that when compared to
non-proliferative lesions, the risk of developing invasive cancer wasatypical ductal hyperplasia;
uctal carcinoma in situ; HR,
ratio; TDLUs, terminal ductal
ion, Wolfson Institute of Pre-
dicine and Dentistry, Queen
London EC1M 6BQ, United
r Ltd. This is an open access articleapproximately doubled when the benign lesion demonstrated hy-
perplasia of the usual type and by 5-fold when atypia was present.
This was a major addition to our understanding as previously risk
was only clearly associated with lesions showing in situ cancer.
Ductal carcinoma in situ (DCIS) is nowconsidered a precursor lesion
as invasive cancer is known to arise directly from it as it is often
seen adjacent to invasive cancers and when DCIS is not fully excised
invasive cancer often occurs in the same region of the breast.
Lobular carcinoma in situ (LCIS) however exhibits different prop-
erties and is indicative of a generalised abnormality affecting the
whole breast. Varying estimates from 2-fold to 13-fold [2e5] of
subsequent cancer risk have been reported, but studies with
stringent pathology criteria and long follow up suggest this risk to
be 8e10-fold [6,7]. Subsequent cancer is equally likely to occur in
either breast [2].
More recently Hartmann and colleagues [8] have explored the
excess risk associated with atypical hyperplasia (AH) in greater
detail. Their work indicates that it can be considered as an inter-
mediate endpoint in the cancer process, and when present largelyunder the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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are not independent but AH largely dominates and overrides other
known risk factors. In particular they found that a family history of
breast cancer did not show any modiﬁcation of the risk associated
with diagnosis of AH, in distinction to the original paper by Dupont
and Page [1]. They also conﬁrmed this was true in other studies
[9e11]. They have also drawn attention to the importance of
involution of breast terminal ductal lobular units (TDLUs) and
number of AH foci as important risk-stratiﬁers. They found that
increasing number of foci of AH increase the risk, and complete
lobular involution substantially lowers the risk, although it does
not reach baseline [10].
Several reports of women with ﬁbroadenoma have also been
published [12]. Ciatto et al. [13] found no increased risk when
ﬁbroadenoma were not biopsied but only diagnosed clinically
(N ¼ 2603, OR ¼ 0.97 (0.70e1.4)) but doubling of risk in those
who had a biopsy (N ¼ 1335, OR ¼ 2.00 (1.4e2.7)). This last
ﬁnding was conﬁrmed by Dupont et al. [14] (OR ¼ 1.61
(1.30e2.0)) who also showed that the risk was greater when
either hyperplasia without atypia (OR ¼ 2.16 (1.20e3.8)) or
atypical hyperplasia was found (OR ¼ 4.77 (1.50e15)), although
the numbers were very small for this last group. McDivitt et al.
[15] have furthermore conﬁrmed these ﬁndings (Table 1). All
these studies were based on excised lesions, where pathologic
features could be examined. However, most benign disease is
cystic, and is often managed by aspiration to relieve pressure and
not excised.
Most studies show little if any excess risk in untreated benign
conditions but an increased risk of cancer in womenwith aspirated
cysts has been consistently reported [16,17]. In particular in a 10
year follow up 1374 women with aspirated but not excised cysts,
Dixon and colleagues [18] found a relative risk for developing
cancer of 2.81 (2.17e3.59), which is similar to that previously re-
ported by Bundred et al. [19].
Impact of preventive therapy
Tamoxifen
Two major prevention trials (NSABP-P1 and IBIS-I) have
included women with atypical hyperplasia as a speciﬁc entryTable 1
The risks of subsequent breast cancer for different types of benign disease.
Type Study
(reference)
N (cancer)/
N (group)
OR (95% CI)
Atypical
hyperplasia (AH)
Nashville [1] 30/232 4.40 (3.10e6.30)
Mayo [8,10,11] 143/698 4.34 (3.66e5.12)
Henry Ford [40] 29/246 4.74 (2.81e7.84)
Nurses's health
study [41]
96/160a 4.11 (2.90e5.83)
McDivitt [15] 66/26a 2.60 (1.60e4.10)
Hyperplasia - no
atypia
McDivitt [15] 124/68a 1.80 (1.30e2.40)
Fibroadenoma
(FA) eclinical only
Ciatto [13] 31/2603 0.97 (0.70e1.40)
FA- all histology Ciatto [13] 41/1335 2.00 (1.40e2.70)
Dupont [14] 87/1835 1.61 (1.30e2.00)
FA e no hyperplasia Dupont [14] 51/1177 1.48 (1.10e1.90)
McDivitt [15] 64/42a 1.70 (1.10e2.50)
FA e hyperplasia
without atypia
Dupont [14] 12/162 2.16 (1.20e3.80)
McDivitt [15] 21/6a 3.70 (1.50e9.20)
FA e with AH Dupont [14] 3/19 4.77 (1.50e15.0)
McDivitt [15] 14/2a 6.90 (1.50e30.6)
Aspirated cysts e no
histology
Dixon [18] 65/1374 2.81 (2.17e3.59)
Bundred [19] 14/352 4.40 (2.41e7.38)
a Case-control.criterion making them eligible to join these placebo controlled
trials of tamoxifen for breast cancer prevention [20,21]. They
comprised 9.1% of the P1 trial and 2.6% of the IBIS-I trial. Both trials
also included women with other types of benign disease e the P1
trial accepted women who had 2 or more breast biopsies and the
IBIS trial accepted women with excised lesions showing hyperpla-
sia if another risk factor was also present (3.3%).
Both trials have reported on the effect of tamoxifen in women
with AH or LCIS. In the P1 trial, a larger effect of tamoxifen
was seen for women with AH (86% reduction) compared to those
in the trial overall (49% reduction) [20]. We have recently re-
ported on the long term follow up of the IBIS-I trial [22] and the
results for AH/LCIS vs. no benign disease are shown in Fig. 1 and
summarized in Table 2. For women with LCIS at entry, no dif-
ference between tamoxifen and placebo was observed (HR ¼ 1.05
(0.48e2.30)). For those with AH, a reduction of 56% was noted
for women receiving tamoxifen compared to those on placebo,
but the numbers were small and the difference was not signiﬁ-
cant. The overall reduction for women with a benign breast
disease at entry was 29% (HR ¼ 0.71 (0.45e1.12)), which was
similar to the overall signiﬁcant reduction in breast cancer inci-
dence for women without benign breast disease (HR ¼ 0.71
(0.60e0.84)) (Table 2).
No details are available speciﬁcally for women with benign
biopsies without histologic evidence of proliferation. Fig. 2 shows
the effect of tamoxifen on women with hyperplasia without
atypia (and other risk factors) compared to women without
proliferative benign lesions. Overall, the 15 year risk was some-
what larger for women with hyperplasia (Table 2) than for
women without benign disease (15 year risk in placebo 16.8% vs.
8.5%), but the relative impact of tamoxifen was similar (HR ¼ 0.67
vs. HR ¼ 0.71).Aromatase inhibitors
Two trials have evaluated aromatase inhibitors for breast
cancer prevention [23,24], and both have explicitly reported on
their effect among women with AH. 8.2% of women in the
MAP.3 trial were entered due to LCIS or AH and a reduction in
breast cancer incidence of 39% was found with exemestane
when compared to placebo (HR ¼ 0.61 (0.20e1.82)). This was
smaller than the reduction in those without LCIS or AH, but the
difference between two groups was not signiﬁcant (p ¼ 0.25)
[24]. The results for the IBIS-II trial, which used anastrozole are
shown in Fig. 1 and Table 3 after a 60-month median follow up.
8.4% of women in the IBIS-II trial were entered due to LCIS or
AH. Breast cancer incidence was reduced by 74% with anastrozole
for women with LCIS at entry (HR ¼ 0.26 (0.06e1.24)) and a
slightly smaller effect was seen for women with AH at entry
(HR ¼ 0.35 (0.12e1.07)), which was still larger than that for other
women in the trial (Table 3). Although no signiﬁcant reduction
was observed for each individual type of benign breast disease,
when combined, a large signiﬁcant 68% signiﬁcant reduction
(P ¼ 0.01) with anastrozole was seen (HR ¼ 0.32 (0.13e0.79))
(Table 3).
In the IBIS-II trial, women with proliferative disease were also
entered on the same basis as for the IBIS-I trial. Here again
the risk was higher than for women without benign disease (10
year risk in placebo arms 14.8% vs. 5.6%) and the effect of anas-
trozole was clearly larger for those with benign breast disease
than in those without (HR ¼ 0.29 vs. HR ¼ 0.50; Table 3, Fig. 3).
However, there was little difference between LCIS, AH and hy-
perplasia of the usual type (10 year risks 17.3%, 13.5%, 14.6%,
respectively) (Table 3, Fig. 3).
Fig. 1. KaplaneMeier curves for womenwith LCIS/AH (solid lines) and womenwithout
benign breast disease (dashed lines) according to treatment allocation in the IBIS-I
trial.
Fig. 2. KaplaneMeier curves for women with hyperplasia without atypia (solid lines)
and women without benign breast disease (dashed lines) according to treatment
allocation in the IBIS-I trial.
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research priorities
Diagnostic challenges
Considerable inter-observer variation exists for diagnosis of
benign breast lesions, particularly for ADH which shares many
features of low grade in situ DCIS and the distinction between these
two lesions remains problematic [25e30]. Lack of uniformly agreed
criteria is one of the reasons for this inconsistency; some base this
distinction on size, with lesions smaller than 2 mm being called
ADHwhile others rely on cytological and architectural features. The
difﬁculty in consistently distinguishing between ADH and low
grade DCIS is one of the reasons for proposals to classify prolifer-
ative ductal lesions in a different manner where both these lesions
belong to grade 1 of Ductal intraepithelial neoplasia, albeit different
sub-grades [25]. While adoption of such new classiﬁcation systems
can potentially reduce inconsistency, it is unclear whether it will
improve breast cancer risk prediction as data for risk stratiﬁcation
based on these new systems do not exist. Improving diagnostic
consistency either through addition of biomarkers [28] or adoption
of newer classiﬁcation systems [25] is a research priority; evalua-
tion of newer classiﬁcation systems through histological reassess-
ment of existing cohorts will be necessary before these are adopted.Risk prediction challenges
Commonly used breast cancer risk predictionmodels, the Breast
Cancer Risk Assessment Tool (BCRAT) [31,32], also known as the
Gail model or the International Breast Cancer Intervention StudyTable 2
Numbers of breast cancer incidence, associated Hazard Ratio (95% CI), and 15-year risk (%)
placebo in the IBIS-I trial.
Tamoxifen (N ¼ 3579)
N (cancer)/N (group)
15 year risk
LCIS 13/44 27.0%
AH 6/90 6.7%
Hyperplasia 12/113 7.7%
LCIS or AH 19/134 13.3%
LCIS or AH or hyperplasia 31/247 10.8%
No benign disease 220/3332 6.5%(IBIS) model, also known as TyrereCuzick model [33] include a
component associated with benign breast disease with special
categorization of atypical hyperplasia. However further validation
of these models when both AH and other important risk factors are
present is needed as notable discrepancies have been observed
[34,35]. Accurate risk-prediction is vital for patients and clinicians
to determine the absolute beneﬁt of any intervention. Therefore,
reﬁnement to improve accuracy of these models and validation of
such reﬁned breast cancer risk prediction models is an important
research need. Currently, it is worth noting that long term follow up
data fromMayo Clinic and Nashville cohorts suggest that AH carries
30% cumulative breast cancer risk over a 25 year period [8].
Challenges to full implementation of preventive strategies in women
with benign disease
A major challenge is full utilisation of preventive therapy in
benign breast disease [36]. Physicians, particularly in primary care,
are often insufﬁciently informed about preventive therapy [37] and
patients often rely on their physician's recommendation [38]. The
decision to not use preventive therapy is often based on an inac-
curate assessment of breast cancer risk, i.e. underestimation of
disease risk and an exaggerated fear of side effects [38,39]. As most
of this evidence is related to tamoxifen, it is possible that agents
with better side-effect proﬁle such as the AIs will be perceived
differently. However, better physician education about preventive
therapy in breast cancer and availability of improved risk-
assessment tools, perhaps with the addition of decision aids dur-
ing physician-patient discussion, will be essential to overcome
these barriers. Development of appropriate decision aids andfor womenwith LCIS, AH, hyperplasia, or no-benign breast disease for tamoxifen vs.
Placebo (N ¼ 3575)
N (cancer)/N (group)
15 year risk HR (95% CI)
12/44 28.0% 1.05 (0.48e2.30)
14/97 14.6% 0.44 (0.17e1.15)
19/126 14.7% 0.67 (0.32e1.37)
26/141 18.7% 0.73 (0.40e1.32)
45/267 16.8% 0.71 (0.45e1.12)
305/3308 8.5% 0.71 (0.60e0.84)
Table 3
Numbers of breast cancer incidence, associated Hazard Ratio (95% CI), and 10-year risk (%) for womenwith LCIS, AH, hyperplasia, or no-benign breast disease for anastrozole vs.
placebo in the IBIS-II trial.
Anastrozole (N ¼ 1920)
N (cancer)/N (group)
10 year risk Placebo (N ¼ 1944)
N (cancer)/N (group)
10 year risk HR (95% CI)
LCIS 2/50 4.6% 8/55 17.3% 0.26 (0.06e1.24)
AH 4/98 5.4% 14/123 13.5% 0.35 (0.12e1.07)
Hyperplasia 0/12 0% 3/22 14.6% 0.00 (0.00e2.29)
LCIS or AH 6/148 5.1% 22/178 14.7% 0.32 (0.13e0.79)
LCIS or AH or hyperplasia 6/160 4.8% 25/200 14.8% 0.29 (0.12e0.71)
No benign disease 41/1760 3.6% 80/1744 5.6% 0.50 (0.34e0.73)
Fig. 3. KaplaneMeier curves for women with LCIS/AH (solid lines) and women
without benign breast disease (dashed lines) according to treatment allocation in the
IBIS-II trial.
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and implementation questions.Conclusions
From these results it is clear that womenwith AH or hyperplasia
without atypia are at an increased risk of breast cancer and pre-
ventive therapy is particularly effective in this group. Improving
diagnostic consistency and breast cancer risk prediction in women
with benign breast disease are important research areas. A larger
effect on breast cancer prevention for women with benign breast
disease was observed with aromatase inhibitors compared to
tamoxifen, making this an attractive agent for postmenopausal
women with proliferative disease. Furthermore, these women are
also an ideal group in which to offer preventive therapy as they
have already entered the medical system and have a right to know
that they are at an increased risk of developing breast cancer and
effective agents exist for reducing that risk. Most women are not
aware of these facts and many clinicians are also insufﬁciently
informed about breast cancer preventive therapy. Now that effec-
tive strategies for risk reduction have been demonstrated, more
effort needs to be expended to make women and their clinicians
aware of these possibilities and to provide help in making decisions
about preventive therapy.Funding
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